LICENSE AGREEMENTLicense Agreement • September 20th, 2007 • Transition Therapeutics Inc. • Medicinal chemicals & botanical products • New York
between Novo Nordisk A/S, a Danish public limited company with its principal place of business at Novo Allé, DK-2880 Bagsvaerd, Denmark (hereinafter referred to as “NN”) and Transition Therapeutics, Inc., an Ontario company with its principal place of business at 415 Yonge Street, Toronto, Ontario, Canada and Waratah Pharmaceuticals Inc., a Canadian company with its principal place of business at 415 Yonge Street, Toronto, Ontario, Canada (hereinafter collectively referred to as “TT”). NN and TT are hereinafter also referred to individually as “Party” and collectively as “Parties.”
